BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 22726969)

  • 1. Evaluation of DCE-MRI postprocessing techniques to assess metastatic bone marrow in patients with prostate cancer.
    Michoux N; Simoni P; Tombal B; Peeters F; Machiels JP; Lecouvet F
    Clin Imaging; 2012; 36(4):308-15. PubMed ID: 22726969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perfusion parameters analysis of the vertebral bone marrow in patients with Ph¹⁻ chronic myeloproliferative neoplasms (Ph(neg) MPN): a dynamic contrast-enhanced MRI (DCE-MRI) study.
    Courcoutsakis N; Spanoudaki A; Maris TG; Astrinakis E; Spanoudakis E; Tsatalas C; Prassopoulos P
    J Magn Reson Imaging; 2012 Mar; 35(3):696-702. PubMed ID: 22069235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffusion and perfusion imaging of bone marrow.
    Biffar A; Dietrich O; Sourbron S; Duerr HR; Reiser MF; Baur-Melnyk A
    Eur J Radiol; 2010 Dec; 76(3):323-8. PubMed ID: 20381277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor infiltration of bone marrow in patients with hemato-logical malignancies: dynamic contrast-enhanced magnetic resonance imaging.
    Zhang L; Mandel C; Yang ZY; Yang Q; Nibbs R; Westerman D; Pitman A
    Chin Med J (Engl); 2006 Aug; 119(15):1256-62. PubMed ID: 16919184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic contrast-enhanced magnetic resonance imaging for evaluating intraosseous cleft formation in patients with osteoporotic vertebral compression fractures before vertebroplasty.
    Lin WC; Chen HL; Lu CH; Wang HC; Wu RW; Cheng YF; Lui CC
    Spine (Phila Pa 1976); 2011 Jul; 36(15):1244-50. PubMed ID: 21217458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local staging of prostate cancer with MRI.
    Soylu FN; Eggener S; Oto A
    Diagn Interv Radiol; 2012; 18(4):365-73. PubMed ID: 22399364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
    Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
    Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of semi-quantitative dynamic contrast-enhanced MRI parameters for prostate cancer in correlation to whole-mount histopathology.
    Isebaert S; De Keyzer F; Haustermans K; Lerut E; Roskams T; Roebben I; Van Poppel H; Joniau S; Oyen R
    Eur J Radiol; 2012 Mar; 81(3):e217-22. PubMed ID: 21349667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy.
    Haider MA; Chung P; Sweet J; Toi A; Jhaveri K; Ménard C; Warde P; Trachtenberg J; Lockwood G; Milosevic M
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):425-30. PubMed ID: 17881141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings.
    Aydin H; Kizilgöz V; Tatar IG; Damar C; Ugan AR; Paker I; Hekimoğlu B
    J Comput Assist Tomogr; 2012; 36(1):30-45. PubMed ID: 22261768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone metastases: evaluation of acuity of lesions using dynamic gadolinium-chelate enhancement, preliminary results.
    Northam M; de Campos RO; Ramalho M; Heredia V; Gonzalez CA; Azevedo RM; Semelka RC
    J Magn Reson Imaging; 2011 Jul; 34(1):120-7. PubMed ID: 21618328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation.
    Hillengass J; Zechmann C; Bäuerle T; Wagner-Gund B; Heiss C; Benner A; Ho A; Neben K; Hose D; Kauczor HU; Goldschmidt H; Delorme S; Moehler T
    Clin Cancer Res; 2009 May; 15(9):3118-25. PubMed ID: 19366830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Principal component analysis of dynamic contrast enhanced MRI in human prostate cancer.
    Eyal E; Bloch BN; Rofsky NM; Furman-Haran E; Genega EM; Lenkinski RE; Degani H
    Invest Radiol; 2010 Apr; 45(4):174-81. PubMed ID: 20177391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence.
    Franiel T; Lüdemann L; Rudolph B; Rehbein H; Staack A; Taupitz M; Prochnow D; Beyersdorff D
    Invest Radiol; 2008 Jul; 43(7):481-7. PubMed ID: 18580330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MR-perfusion (MRP) and diffusion-weighted imaging (DWI) in prostate cancer: quantitative and model-based gadobenate dimeglumine MRP parameters in detection of prostate cancer.
    Scherr MK; Seitz M; Müller-Lisse UG; Ingrisch M; Reiser MF; Müller-Lisse UL
    Eur J Radiol; 2010 Dec; 76(3):359-66. PubMed ID: 20471189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma.
    Hillengass J; Wasser K; Delorme S; Kiessling F; Zechmann C; Benner A; Kauczor HU; Ho AD; Goldschmidt H; Moehler TM
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):475-81. PubMed ID: 17255268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limitations of single slice dynamic contrast enhanced MR in pharmacokinetic modeling of bone sarcomas.
    Toms AP; White LM; Kandel R; Bleakney RR; Noseworthy M; Lee S; Blackstein ME; Wunder J
    Acta Radiol; 2009 Jun; 50(5):512-20. PubMed ID: 19431058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic significance of high signal intensity on diffusion-weighted MR imaging in the ureter, urethra, prostate and bone of patients with bladder cancer.
    Takeuchi M; Suzuki T; Sasaki S; Ito M; Hamamoto S; Kawai N; Kohri K; Hara M; Shibamoto Y
    Acad Radiol; 2012 Jul; 19(7):827-33. PubMed ID: 22341371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Description of magnetic resonance imaging-derived enhancement variables in pathologically confirmed prostate cancer and normal peripheral zone regions.
    Zelhof B; Lowry M; Rodrigues G; Kraus S; Turnbull L
    BJU Int; 2009 Sep; 104(5):621-7. PubMed ID: 19281464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging.
    Delongchamps NB; Rouanne M; Flam T; Beuvon F; Liberatore M; Zerbib M; Cornud F
    BJU Int; 2011 May; 107(9):1411-8. PubMed ID: 21044250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.